RHYTHM PHARMACEUTICALS, INC.

RYTM
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001649904

Price chart

Open-market purchases and sales by RYTM insiders, newest first.

Insider trades
Filed (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
Sep 14, 20267:37 PM ETSep 14, 2026Meeker David PPresident and CEOSSaleCommon Stock−50K$102.6688−$5.13M239.26K−17.3%SEC10b5-1
Sep 1, 20264:22 PM ETAug 31, 2026Smith Hunter CChief Financial OfficerSSaleCommon Stock−62.77K$105.4563−$6.62M114.02K−35.5%SEC10b5-1
Aug 17, 20266:00 PM ETAug 13, 2026Shulman JosephChief Technical OfficerSSaleCommon Stock−5.08K$119.75−$608.21K15.92K−24.2%SEC10b5-1
Aug 17, 20265:57 PM ETAug 13, 2026Garfield AlastairChief Scientific OfficerSSaleCommon Stock−7.76K$117.5709−$912.7K2.3K−77.2%SEC10b5-1
Aug 14, 20267:04 PM ETAug 13, 2026Chien JenniferEVP, Head of North AmericaSSaleCommon Stock−75.83K$117.3818−$8.9M0−100.0%SEC10b5-1

The largest institutional positions in RYTM at the end of Q2 2026.

Institutions holding RYTM in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
RA CAPITAL MANAGEMENT, L.P.6,666,837$740.22M6.43%00.0%Unchanged
BlackRock, Inc.6,156,902$683.6M0.01%−80,249−1.3%Reduced
BAKER BROS. ADVISORS LP5,604,483$622.27M3.12%00.0%Unchanged
PRIMECAP MANAGEMENT CO/CA/3,168,853$351.84M0.21%−248,656−7.3%Reduced
VANGUARD PORTFOLIO MANAGEMENT LLC3,136,895$348.29M0.02%+96,177+3.2%Added